Overview of Study Design of the COCOON Trial

Overview of Study Design of the COCOON Trial

Panelists discuss how the COCOON trial demonstrated that enhanced dermatologic management significantly reduced grade 2 or higher skin-related adverse events (38% vs 76%) compared with standard of care for patients receiving amivantamab plus lazertinib.

COCOON Regimen Demonstrates Improvement in Dermatologic Toxicities - ILCN.org (ILCN/WCLC)

The ongoing COCOON study of a prophylactic dermatologic regimen in reducing the incidence of skin- and nail-adverse reactions in patients treated with amivantamab plus lazertinib demonstrated “early success” in meeting its phase II primary endpoint, according to a March 27 presentation during the European Lung Cancer Congress (ELCC). The one-to-one randomized study included 102 patients with EGFR-positive non-small cell lung cancer (NSCLC) recei…

Clinical Approaches for Dermatologic AEs Associated With Amivantamab + Lazertinib in Advanced NSCLC

A panelist discusses how prophylactic dermatologic management, including the proactive use of moisturizers, topical steroids, and antibiotics, significantly improves the tolerability and adherence to first-line treatment with amivantamab and lazertinib for advanced non–small cell lung cancer (NSCLC) by reducing the severity of dermatologic adverse events (DAEs) and preventing treatment interruptions.